| Identification | Back Directory | [Name]
L-Valine, L-alanyl-L-glutaminylglycyl- | [CAS]
503844-09-5 | [Synonyms]
NMPF46
NMPF-46
NMPF 46
L-Valine, L-alanyl-L-glutaminylglycyl- | [Molecular Formula]
C15H27N5O6 | [MOL File]
503844-09-5.mol | [Molecular Weight]
373.4 |
| Chemical Properties | Back Directory | [Boiling point ]
856.8±65.0 °C(Predicted) | [density ]
1.267±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.35±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
EA-230 is a synthetic oligopeptide originally derived from beta-human chorionic gonadotropin (beta-hCG) lysates. EA-230 has anti-inflammatory effects and can be used for the research of sepsis[1]. | [in vivo]
EA-230 (30-50 mg/kg; i.p.; twice daily for four consecutive days) improves survival and attenuate loss of kidney function in a mouse model of renal ischemia/reperfusion injury (IRI) and ischemia-induced delayed graft function after allogenic kidney transplantation[1]. | Animal Model: | Male C57Bl/6 mice, ischemia reperfusion injury model[1] | | Dosage: | 20, 30, 40 or 50 mg/kg | | Administration: | Intraperitoneal injection, twice daily for four consecutive days | | Result: | Improved survival markedly. With doses between 30–50 mg/kg survival reached 56–62%, the low dose treatment with 20 mg/kg did not have a beneficial effect. Significantly increased renal blood flow (RBF), attenuated CTGF up-regulation, enhanced tubular epithelial cell regeneration and attenuated TGF-beta activation. |
| [References]
[1] Gueler F, et al. A novel therapy to attenuate acute kidney injury and ischemic allograft damage after allogenic kidney transplantation in mice. PLoS One. 2015 Jan 24;10(1):e0115709. DOI:10.1371/journal.pone.0115709 |
|
|